MCA logo
MCA logo
MCA logo

PUBLIC PORTAL

MCA logo

MEDICALLY REVIEWED

Semaglutide (Rybelsus®) receives FDA approval as first line treatment for Type 2 Diabetes Mellitus

Novo Nordisk
Semaglutide, available in oral and subcutaneous dosage forms, is a selective glucagon-like peptide-1 receptor agonist with 3 main mechanisms of action.

Log In as a healthcare professional to read the full article.

ShanPing

ShanPing

Shan is a licensed pharmacist working in the acute setting in a restructured hospital in Singapore. With a passion for communicating the technicalities of medicine artfully through the written word, she continues honing her craft through creating purposeful content within the healthcare industry.

Share via

Also worth reading

People also read:

Looking for health news and information? Stay updated with MCA’s health articles!

By clicking Submit, I agree to receive health newsletters and updates on upcoming health events from Medical Channel Asia and its partners.

About Us

Advertise

Contact Us

My Account

Privacy Policy

FOLLOW MCA

Facebook-f Tiktok Youtube Instagram Linkedin-in Telegram-plane

ACCREDITATIONS

Looking for health news and information? Stay updated with MCA’s health articles!

By clicking Submit, I agree to receive health newsletters and updates on upcoming health events from Medical Channel Asia and its partners.

About Us

Advertise

Contact Us

Privacy Policy

FOLLOW MCA

Facebook-f Tiktok Youtube Instagram Linkedin-in Telegram-plane

ACCREDITATIONS

Copyright © Medical Channel Asia 2022. All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.